source
- J&J strikes up to $925M deal with Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson announced a collaboration with Flagship Pioneering’s Sail Biomedicines to develop in vivo CAR‑T therapies for immune‑mediated diseases. The agreement provides up to $925 million i…
- FDA panel rejects Capricor's Duchenne drug, citing insufficient efficacy dataThe U.S. Food and Drug Administration advisory committee voted 9-to-3 against a Capricor Therapeutics candidate for Duchenne muscular dystrophy. The panel said the clinical data did not provide sub…